A Trial of Brexpiprazole in the Treatment of Borderline Personality Disorder

Study Identifier:

331-201-00242

ClinicalTrials.gov Identifier:

NCT04100096

EudraCT Identifier:

N/A

Sponsor:

Otsuka Pharmaceutical Development & Commercialization, Inc.

Study Contact Information:

N/A

Study Complete

Subscribe to Updates

Results Available

Study Protocol

Available Languages: English

Download document(s)

Statistical Analysis Plan

Available Languages: English

Download document(s)

Study Details

Medical Condition

Borderline Personality Disorder

Study Drug

Drug: Brexpiprazole

Date

Oct 2019 - Jun 2021

Phase 1

Phase 2

Phase 3

Phase 4

N/A

Patient Requirements

Sex: Female & Male

Age: 18 - 65 Years

Requirements Information

Protocol Summary

There are currently no pharmacological treatments approved to treat borderline personality disorder (BPD). This trial will be conducted to evaluate the efficacy and safety of brexpiprazole for the treatment of participants diagnosed with BPD to provide a pharmacological treatment for BPD.

Study Locations

Location

Status

Location

Pillar Clinical Research

Bentonville, Arkansas, United States, 72712

Status

N/A

Location

CI Trials

Bellflower, California, United States, 90706

Status

N/A

Location

Care Access Research Beverly Hills

Beverly Hills, California, United States, 90212

Status

N/A

Location

OM Research LLC

Lancaster, California, United States, 93534

Status

N/A

Location

CalNeuro Research Group

Los Angeles, California, United States, 90024

Status

N/A

Location

Excell Research

Oceanside, California, United States, 92056

Status

N/A